Dawn Midwinter

1.1k total citations
32 papers, 668 citations indexed

About

Dawn Midwinter is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Dawn Midwinter has authored 32 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Dawn Midwinter's work include Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers), Asthma and respiratory diseases (14 papers) and Inhalation and Respiratory Drug Delivery (9 papers). Dawn Midwinter is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers), Asthma and respiratory diseases (14 papers) and Inhalation and Respiratory Drug Delivery (9 papers). Dawn Midwinter collaborates with scholars based in United Kingdom, United States and Denmark. Dawn Midwinter's co-authors include David Halpin, Neil Barnes, David A. Lipson, Robert A. Wise, Peter Lange, W. R. L. James, MeiLan K. Han, Fernando J. Martínez, Dave Singh and Gerard J. Criner and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Dawn Midwinter

28 papers receiving 660 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn Midwinter United Kingdom	12	579	271	94	57	57	32	668
Shani Alston United States	8	145 0.3×	346 1.3×	233 2.5×	58 1.0×	26 0.5×	13	661
Simone Hummler Germany	11	217 0.4×	147 0.5×	197 2.1×	43 0.8×	12 0.2×	17	432
Benoît Colinet Belgium	9	315 0.5×	46 0.2×	193 2.1×	70 1.2×	14 0.2×	22	512
N.J.J. Schlösser Netherlands	8	479 0.8×	284 1.0×	155 1.6×	51 0.9×	7 0.1×	16	593
Nathan Hambly Canada	14	412 0.7×	200 0.7×	24 0.3×	44 0.8×	36 0.6×	35	524
George Youssef Australia	10	336 0.6×	364 1.3×	40 0.4×	98 1.7×	190 3.3×	22	687
Annamaria Vinciguerra Italy	13	373 0.6×	247 0.9×	119 1.3×	18 0.3×	9 0.2×	45	618
Eija‐Riitta Salomaa Finland	10	474 0.8×	119 0.4×	162 1.7×	29 0.5×	5 0.1×	18	628
Kjersti Hornslien Norway	9	206 0.4×	42 0.2×	364 3.9×	36 0.6×	27 0.5×	13	464
Fredrik Wiklund Sweden	9	528 0.9×	344 1.3×	190 2.0×	38 0.7×	8 0.1×	20	655

Countries citing papers authored by Dawn Midwinter

Since Specialization

Citations

This map shows the geographic impact of Dawn Midwinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Midwinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Midwinter more than expected).

Fields of papers citing papers by Dawn Midwinter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Midwinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Midwinter. The network helps show where Dawn Midwinter may publish in the future.

Co-authorship network of co-authors of Dawn Midwinter

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Midwinter. A scholar is included among the top collaborators of Dawn Midwinter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Midwinter. Dawn Midwinter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halpin, David, Alan Martin, Dhvani Shah, et al.. (2022). Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. International Journal of COPD. Volume 17. 2745–2755. 10 indexed citations

Panettieri, Reynold A., Carlos A. Camargo, Tariq Cheema, et al.. (2022). Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial. International Journal of COPD. Volume 17. 2043–2052. 3 indexed citations

Criner, Gerard J., David Halpin, MeiLan K. Han, et al.. (2022). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respiratory Medicine. 205. 107040–107040. 6 indexed citations

Wells, J. Michael, Gerard J. Criner, David Halpin, et al.. (2022). Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 10(1). 33–45. 13 indexed citations

Panettieri, Reynold A., Carlos A. Camargo, Tariq Cheema, et al.. (2021). EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON SEVERE EXACERBATION RATES COMPARED WITH TWICE-DAILY BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD: A POST HOC ANALYSIS OF THE FULFIL STUDY. CHEST Journal. 160(4). A1818–A1821.

Horne, Benjamin D., Dawn Midwinter, Catherine Scott-Wilson, et al.. (2021). Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness. International Journal of COPD. Volume 16. 41–51.

Halpin, David, Sally Worsley, Afisi Ismaila, et al.. (2021). INTREPID: single-versusmultiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research. 7(2). 950–2020. 46 indexed citations

Thomashow, Byron, Marjorie Stiegler, Gerard J. Criner, et al.. (2021). Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 9(1). 68–79. 6 indexed citations

Mammen, Manoj J., Tara F. Carr, Gerard J. Criner, et al.. (2021). All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial. A2241–A2241. 1 indexed citations

10.

Wise, Robert A., Mona Bafadhel, Courtney Crim, et al.. (2021). Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review. 30(162). 210124–210124. 8 indexed citations

11.

Lipson, David A., Courtney Crim, Gerard J. Criner, et al.. (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 201(12). 1508–1516. 146 indexed citations

12.

Barnes, Neil, Takeo Ishii, Nobuyuki Hizawa, et al.. (2018). The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world. International Journal of COPD. Volume 13. 433–440. 11 indexed citations

13.

Palen, Job van der, C. Dawson, W. R. L. James, et al.. (2018). A randomized, open-label, single-visit crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. International Journal of COPD. Volume 13. 2515–2523. 28 indexed citations

14.

Bhatt, Surya P., John Cockcroft, Jie Wang‐Jairaj, et al.. (2017). A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD. International Journal of COPD. Volume 12. 351–365. 15 indexed citations

15.

Siler, Thomas M., Atsushi Nagai, Catherine Scott-Wilson, Dawn Midwinter, & Courtney Crim. (2016). A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respiratory Medicine. 123. 8–17. 18 indexed citations

16.

Hilton, Emma, Christopher Compton, Dawn Midwinter, & N. Barnes. (2016). P142 The distribution of blood eosinophil count in a copd clinical trials database: comparing the uk with the rest of the world. Thorax. 71(Suppl 3). A159.2–A160.

17.

Barnes, Neil, W. R. L. James, Dawn Midwinter, et al.. (2015). Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 193(7). 717–726. 85 indexed citations

18.

Pépin, Jean‐Louis, John R. Cockcroft, Dawn Midwinter, et al.. (2014). Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD. CHEST Journal. 146(6). 1521–1530. 23 indexed citations

19.

Campo, J.M. del, Ricardo Hitt, P. Sebastian, et al.. (2011). Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. British Journal of Cancer. 105(5). 618–627. 89 indexed citations

20.

Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact